^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    magrolimab (ONO-7913)

    i
    Company:
    Gilead, Ono Pharma
    Drug class:
    CD47 inhibitor
    Related drugs:
    Apply
    Magrolimab, Azacitidine, and Venetoclax for the Treatment of Acute Myeloid Leukemia (NCI-2020-04163) (NCT04435691)
    Phase 1/2
    M.D. Anderson Cancer Center
    Active, not recruiting
    Last update posted :
    02/06/2025
    Initiation :
    07/28/2020
    Primary completion :
    02/28/2026
    Completion :
    02/28/2026
    TP53
    |
    TP53 mutation • TP53 deletion
    |
    Venclexta (venetoclax) • azacitidine • magrolimab (ONO-7913)
    Venetoclax With Obinutuzumab and Magrolimab (VENOM) in Relapsed and Refractory Indolent B-cell Malignancies (NCT04599634)
    Phase 1
    National Cancer Institute (NCI)
    Completed
    Last update posted :
    02/04/2025
    Initiation :
    12/16/2021
    Primary completion :
    03/29/2024
    Completion :
    06/20/2024
    TP53 • BCL2
    |
    TP53 mutation • CD20 positive
    |
    Venclexta (venetoclax) • Gazyva (obinutuzumab) • magrolimab (ONO-7913) • methylprednisolone acetate • methylprednisolone sodium succinate
    Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatments and Combinations in Patients With Urothelial Carcinoma (MORPHEUS-UC) (MORPHEUS mUC) (NCT03869190)
    Phase 1/2
    Hoffmann-La Roche
    Active, not recruiting
    Last update posted :
    01/03/2025
    Initiation :
    06/01/2019
    Primary completion :
    10/03/2024
    Completion :
    05/21/2026
    PD-L1
    |
    cisplatin • Tecentriq (atezolizumab) • gemcitabine • Zejula (niraparib) • Trodelvy (sacituzumab govitecan-hziy) • Padcev (enfortumab vedotin-ejfv) • magrolimab (ONO-7913) • Actemra IV (tocilizumab) • tiragolumab (RG6058) • RG7827 • lomvastomig (RG7769)
    Study of Magrolimab Combination Therapy in Patients With Head and Neck Squamous Cell Carcinoma (ELEVATE HNSCC) (NCT04854499)
    Phase 2
    Gilead Sciences
    Active, not recruiting
    Last update posted :
    05/20/2024
    Initiation :
    09/07/2021
    Primary completion :
    07/01/2025
    Completion :
    07/01/2025
    PD-L1
    |
    Keytruda (pembrolizumab) • cisplatin • carboplatin • docetaxel • 5-fluorouracil • Yutuo (zimberelimab) • magrolimab (ONO-7913)
    Testing the Addition of Immunotherapy With Hu5F9-G4 (Magrolimab) to the Usual PARP Inhibitor, Olaparib for Treatment of Metastatic or Recurrent Breast or Castrate-Resistant Prostate Cancer With BRCA Mutations (NCT05807126)
    Phase 1
    National Cancer Institute (NCI)
    Withdrawn
    Last update posted :
    05/02/2024
    Initiation :
    03/05/2024
    Primary completion :
    12/06/2026
    Completion :
    12/06/2026
    IFNG • CD47 • BRCA • RAD51C • RAD51D • TGFB1 • IRF3
    |
    HR positive • BRCA mutation • CD47 expression
    |
    Lynparza (olaparib) • magrolimab (ONO-7913)
    Phase II Trial of Magrolimab and Cetuximab With Pembrolizumab or Docetaxel for Recurrent/Metastatic Head Neck Squamous Cell Carcinoma (NCT06046482)
    Phase 2
    M.D. Anderson Cancer Center
    Suspended
    Last update posted :
    04/12/2024
    Initiation :
    11/28/2023
    Primary completion :
    11/30/2027
    Completion :
    11/30/2029
    PD-L1 • SIRPA
    |
    Keytruda (pembrolizumab) • Erbitux (cetuximab) • docetaxel • magrolimab (ONO-7913)
    Study of Magrolimab (Hu5F9-G4) in Combination With Avelumab in Solid Tumor Participants and Checkpoint-Inhibitor-Naive Ovarian Cancer Participants Who Progress Within 6 Months of Prior Platinum Chemotherapy (NCT03558139)
    Phase 1
    Gilead Sciences
    Completed
    Last update posted :
    04/01/2024
    Initiation :
    05/23/2018
    Primary completion :
    12/03/2020
    Completion :
    12/03/2020
    PD-L1
    |
    PD-L1 expression
    |
    Bavencio (avelumab) • magrolimab (ONO-7913)
    Study of Magrolimab in Patients With Solid Tumors (ELEVATELung&UC) (NCT04827576)
    Phase 2
    Gilead Sciences
    Active, not recruiting
    Last update posted :
    03/21/2024
    Initiation :
    10/01/2021
    Primary completion :
    08/01/2024
    Completion :
    03/01/2025
    EGFR • ALK • ROS1 • NTRK
    |
    MET exon 14 mutation
    |
    docetaxel • magrolimab (ONO-7913)
    Study of Magrolimab Combination Therapy in Patients With Non-Surgically Removable Locally Advanced or Metastatic Triple-Negative Breast Cancer (ELEVATE TNBC) (NCT04958785)
    Phase 2
    Gilead Sciences
    Active, not recruiting
    Last update posted :
    03/15/2024
    Initiation :
    12/14/2021
    Primary completion :
    08/01/2024
    Completion :
    01/01/2025
    PD-L1
    |
    PD-L1 expression • PD-L1 negative
    |
    albumin-bound paclitaxel • Trodelvy (sacituzumab govitecan-hziy) • magrolimab (ONO-7913)
    Study of Magrolimab (Hu5F9-G4) in Combination With Cetuximab in Participants With Solid Tumors and Advanced Colorectal Cancer (NCT02953782)
    Phase 1b/2
    Gilead Sciences
    Completed
    Last update posted :
    03/01/2021
    Initiation :
    11/02/2016
    Primary completion :
    02/10/2020
    Completion :
    02/10/2020
    KRAS
    |
    KRAS mutation • KRAS wild-type • RAS wild-type
    |
    Erbitux (cetuximab) • oxaliplatin • irinotecan • magrolimab (ONO-7913)